BiotechTube

Miricorilant + Fluvoxamine

Phase 1Completed
0 views this week 0 watching💤 Quiet
Interest: 26/100
26
Hype Score

Development Stage

✓
Pre-clinical
2
Phase 1
3
Phase 2
4
Phase 3
5
Approved
Indication / Disease

Antipsychotic Induced Weight Gain

Conditions

Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH)

Trial Timeline

Jan 24, 2023 → Feb 23, 2023

NCT ID
NCT05712265

About Miricorilant + Fluvoxamine

Miricorilant + Fluvoxamine is a phase 1 stage product being developed by Corcept Therapeutics for Antipsychotic Induced Weight Gain. The current trial status is completed. This product is registered under clinical trial identifier NCT05712265. Target conditions include Antipsychotic Induced Weight Gain, Non-alcoholic Steatohepatitis (NASH).

Hype Score Breakdown

Clinical
6
Activity
8
Company
12
Novelty
0
Community
0

Clinical Trials (1)

NCT IDPhaseStatus
NCT05712265Phase 1Completed

Competing Products

3 competing products in Antipsychotic Induced Weight Gain

See all competitors
ProductCompanyStageHype Score
Miricorlilant + Miricorlilant + PlaceboCorcept TherapeuticsPhase 2
32
Miricorilant + PlaceboCorcept TherapeuticsPhase 2
32
Olanzapine + CORT118335 + PlaceboCorcept TherapeuticsPhase 1
26